A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved drug in the market-and an experimental drug called FGTI-2734, which could make precision medicine more effective for patients with a highly resistant form of lung cancer. The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C mutation-a driver in about 14% of non-small cell lung cancers.
FDA-approved drugs sotorasib and adagrasib have given new hope to some patients by targeting this KRAS G12C mutation, but the majority of tumors fight back, either resisting treatment from the start or relapsing within months….